Urothelial Carcinoma starts when cells that make up the urinary bladder becomes cancerous. Bladder neoplasms can arise from any of the four bladder wall layers. They are broadly classified as either epithelial or non-epithelial (mesenchymal), with over 95% being epithelial. Epithelial tumors with differentiation toward normal urothelium are urothelial/ urinary carcinoma (UC). Other types of bladder neoplasms, namely, squamous cell carcinoma, adenocarcinoma, small cell carcinoma and sarcoma account for 2–5% of bladder neoplasms.
The majority of UC occurs in males with approximately has two-to-three fold greater incidence as compared to females. UC is the invasion of the basement membrane or lamina propria by neoplastic cells of urothelial origin. The main causative agents of upper tract UC and urinary bladder cancer include cigarette smoking and workrelated exposure, while other factors are more specific to the carcinogenesis of upper tract UC (i.e., Balkan endemic nephropathy).
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/urothelial-carcinoma-market
The Urothelial Carcinoma market report also covers emerging drugs, current treatment practices, Urothelial Carcinoma market share of the individual therapies, current and forecasted Urothelial Carcinoma Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Urothelial Carcinoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Urothelial Carcinoma Market Key Facts
As per Delveinsight estimates, among EU5 countries, Germany had the maximum total cases of locally advanced/metastatic UC with 15,192 cases in 2017.
The total incident population of UC in the seven major markets was found to be 243,151 cases in 2017, whereas the total cases of locally advanced/metastatic UC in the 7MM were 96,711 cases in 2017. The diagnosed incident population of UC in the 7MM is expected to increase at a CAGR for the study period, i.e., 2017–2030.
Key Benefits of Urothelial Carcinoma Market Report
-
Urothelial Carcinoma market report provides an in-depth analysis of Urothelial Carcinoma Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Urothelial Carcinoma market report will help in developing business strategies by understanding the Urothelial Carcinoma Market trends & developments, key players and future market competition that will shape and drive the Urothelial Carcinoma market in the upcoming years.
-
The Urothelial Carcinoma market report covers Urothelial Carcinoma current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Urothelial Carcinoma market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
UC, also known as transitional cell carcinoma (TCC), is characterized by cancer beginning in the urothelial cells lining the bladder, it is one of the most common forms of bladder cancer (BC). Treatment for Urothelial Carcinoma (UC) can be employed in different classes of chemotherapy, immunotherapy, radiation therapy, target specific therapy, and surgical treatment. Metastatic urothelial carcinoma has shown poor survival when treated with chemotherapy; however, due to the advancements in the treatment of new immunotherapies, more alternatives are available.
The Urothelial Carcinoma market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Urothelial Carcinoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Urothelial Carcinoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Increasing awareness, introduction of novel drugs and changing lifestyle are some of the key factors driving the growth of Urothelial Carcinoma market globally
Urothelial Carcinoma Epidemiology
Bladder cancer has also been segregated on the basis of severity of urothelial carcinoma, i.e., non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) at the time of diagnosis. Delveinsight found 50,632 and 21,700 cases for NMIBC and MIBC, respectively, in 2017 in the United States.
The Urothelial Carcinoma epidemiology section covers insights about historical and current Urothelial Carcinoma patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Urothelial Carcinoma Drugs Uptake and Key Market Players
The Urothelial Carcinoma Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Urothelial Carcinoma market or expected to get launched in the market during the study period. The analysis covers Urothelial Carcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
UC, also known as transitional cell carcinoma (TCC), is characterized by cancer beginning in the urothelial cells lining the bladder, it is one of the most common forms of bladder cancer (BC). Treatment for Urothelial Carcinoma (UC) can be employed in different classes of chemotherapy, immunotherapy, radiation therapy, target specific therapy, and surgical treatment. Metastatic urothelial carcinoma has shown poor survival when treated with chemotherapy; however, due to the advancements in the treatment of new immunotherapies, more alternatives are available.
Some of the key companies in the Urothelial Carcinoma Market includes:
Merck
Bristol-Myers Squibb
Genentech
Merck
AstraZeneca
Janssen
Astellas Pharma/Seattle Genetics
Eli Lilly and Company
QED Therapeutics
Bayer
Incyte Corporation
Immunomedics
Nektar Therapeutics
Rexahn Pharmaceuticals
Acerta Pharma
Infinity Pharma
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Urothelial Carcinoma Competitive Intelligence Analysis
4. Urothelial Carcinoma Market Overview at a Glance
5. Urothelial Carcinoma Disease Background and Overview
6. Urothelial Carcinoma Patient Journey
7. Urothelial Carcinoma Epidemiology and Patient Population
8. Urothelial Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Urothelial Carcinoma Unmet Needs
10. Key Endpoints of Urothelial Carcinoma Treatment
11. Urothelial Carcinoma Marketed Products
12. Urothelial Carcinoma Emerging Therapies
13. Urothelial Carcinoma Seven Major Market Analysis
14. Attribute Analysis
15. Urothelial Carcinoma Market Outlook (7 major markets)
16. Urothelial Carcinoma Access and Reimbursement Overview
17. KOL Views on the Urothelial Carcinoma Market.
18. Urothelial Carcinoma Market Drivers
19. Urothelial Carcinoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Urothelial Carcinoma Epidemiology Forecast to 2030
DelveInsight’s Urothelial Carcinoma – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Urothelial Carcinoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Urothelial Carcinoma Pipeline Insights, 2020
Urothelial Carcinoma Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Urothelial Carcinoma market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/